2-(2-amino-4-thiazolyl)-2-[[(Z)-(p-nitrobenzyloxycarbonyl)-methoxy]-imino]acetic acid-2-benzothiazolyl-thioester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-amino-4-thiazolyl)-2-[[(Z)-(p-nitrobenzyloxycarbonyl)-methoxy]-imino]acetic acid-2-benzothiazolyl-thioester
• 英文别名: (Z)-2-(2-amino-4-thiazolyl)-2-[[(p-nitrobenzyloxycarbonyl)methoxy]imino]-acetic acid 2-benzthiazolyl thioester；2-(2-amino-4-thiazolyl)-2-[[(Z)-(p-nitrobenzyloxycarbonyl)methoxy]imino]-acetic acid 2-benzthiazolyl thioester；1,3-benzothiazol-2-ylsulfanyl (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[2-[(4-nitrophenyl)methoxy]-2-oxoethoxy]iminoacetate
• 化学式: C₂₁H₁₅N₅O₇S₃
• 分子量: 545.577
• InChiKey: QPHNNDQHWRKFAO-BWAHOGKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  254
• 氢给体数：
  1
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  2-(2-amino-4-thiazolyl)-2-[[(Z)-(p-nitrobenzyloxycarbonyl)-methoxy]-imino]acetic acid-2-benzothiazolyl-thioester 、 (3S,4S)-3-amino-4-carbamoyloxymethyl-2-azetidinone-1-sulfonic acid 生成 (3S,4S)-3-[(Z)-2-(2-amino-4-thiazolyl)-2-[[(p-nitrobenzyloxycarbonyl)methoxy]imino]acetamido]-4-carbamoyloxymethyl-2-oxo-1-azetidinesulphonic acid sodium salt
  参考文献：
  名称：

  .beta.-Lactams

  摘要：

  提供了光学均匀的β-内酰胺，其结构式如下：其中Z是易于水解的酰基，R.sup.1是氨基或可转化为氨基的基团，R.sup.2是氢或易于水解的保护基团，R.sup.3和R.sup.4分别是低碳氢基团，可选地含氧，并通过碳原子连接，这些基团也可以相互连接形成环，但R.sup.1是易于水解的酰胺基团当R.sup.2为氢时，以及相应的光学对映体，它们的制造和用于制造抗微生物活性的β-内酰胺以及在其制造中可用的新型中间体。

  公开号：

  US04576751A1
• 作为产物：
  描述：

  N-甲基吗啉 、 二硫化二苯并噻唑 在 亚磷酸三乙酯 作用下， 以 乙腈 为溶剂， 生成 2-(2-amino-4-thiazolyl)-2-[[(Z)-(p-nitrobenzyloxycarbonyl)-methoxy]-imino]acetic acid-2-benzothiazolyl-thioester
  参考文献：
  名称：

  4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their

  摘要：

  揭示的是一般式为：##STR1##的化合物，其中R.sup.1是氢原子或较低的烷基基团，R.sup.2是氢原子或酯基团，所述衍生物具有(3S,4S)-构型；以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性，并且作为人类和驯养动物的药物具有价值。

  公开号：

  US04572801A1

文献信息

• Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid
  申请人：Hoffmann-La Roche Inc.

  公开号：US04652651A1

  公开（公告）日：1987-03-24

  The manufacture of 1-sulpho-2-oxazetidine derivatives of the formula ##STR1## in which Het is an optionally amino-substituted, 5- or 6-membered, aromatic heterocycle containing 1 or 2 nitrogen atoms and optionally also an oxygen or sulphur atom, R.sup.1 is hydrogen, lower alkyl, phenyl-lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, phenyl-lower-alkoxycarbonyl-lower alkyl, nitrophenyl-lower-alkoxycarbonyl-lower alkyl or carboxy-lower alkyl and R.sup.2 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxycarbonyl, lower alkanoyloxy-lower alkyl, lower alkoxycarbonyl-lower alkenyl, hydroxyiminomethyl, lower alkoxyiminomethyl, carbamoyl, carbamoyl-lower alkenyl or carbamoyloxy-lower alkyl, the group .dbd.NOR.sup.1 being present at least partially in the syn-form, in racemic form or in the form of the 3S-enantiomer, and of readily hydrolyzable esters and pharmaceutically compatible salts of these compounds, by acylating a compound of the formula ##STR2## in which R.sup.20 equals R.sup.2 or can also represent a 2,2-dimethyl-1,3-dioxolan-4-yl group and R.sup.3 is hydrogen or sulpho, or a salt thereof with a thioester of the formula ##STR3## in which Het is as above and R.sup.10 has any of the values of R.sup.1 except carboxy-lower alkyl, and can also represent a tri-lower alkyl-silyl-lower-alkoxycarbonyl-lower alkyl group or a carboxy-lower alkyl group converted into a readily hydrolyzable ester group, and the group .dbd.NOR.sup.10 is present at least partially in the syn-form, and carrying out subsequent steps (N-sulphonation, conversion of R.sup.20 into R.sup.2, R.sup.10 into R.sup.1), some of which are optional. The invention also provides certain novel products of formula I and benzthiazolyl thioesters of formula III per se and the preparation of the benzthiazolyl thioesters by esterifying corresponding carboxylic acids. Finally, the invention provides a process for the preparation of carboxylic acids in which R.sup.1 is t-alkoxycarbonylmethyl. The compounds of formula I have antimicrobial activity.

  该专利描述了一种制备1-磺酸-2-噁唑环丙烷衍生物的方法，其化学式为##STR1##其中Het是一个含有1或2个氮原子和可能还有一个氧原子或硫原子的可选氨基取代的5或6元芳香杂环，R.sup.1是氢、低烷基、苯基-低烷基、低烷酰、低烷氧羰基、低烯基-低烷基、低烷氧羰基-低烷基、苯基-低烷氧羰基-低烷基、硝基苯基-低烷氧羰基-低烷基或羧基-低烷基，R.sup.2是氢、低烷基、低烯基、低炔基、低烷氧羰基、低烷酰氧基-低烷基、低烷氧羰基-低烯基、羟基亚胺甲基、低烷氧亚胺甲基、氨甲酰基、氨甲酰基-低烯基或氨甲酰氧基-低烷基，.dbd.NOR.sup.1基团至少部分以syn-形式存在，是外消旋形式或3S-对映体形式，以及这些化合物的易水解酯和药用兼容盐的制备方法。
• 1-Sulfo-2-azetidinone derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0093376A2

  公开（公告）日：1983-11-09

  A 1-sulfo-2-oxoazetidine derivative of the formula wherein R8 is -COQ° (Q° is an amino group which may optionally be protected or substituted), -COQ5 (Q5 is a hydroxyl group which may optionally be protected), -(CH2)na- R4a (na is an integer of 1 to 3: R4a is a hydrogen atom or a carbamoylamino, N-sulfocarbamoylamino, carbamoyl, carbamoyloxy, N-sulfocarbamoyloxy, haloalkylcarbonylcarbamoyloxy, alkylsulfonyloxy, pyridinio, alkoxy, alkylsulfinyl, alkylsulfonyl, halogenoalkylcarbonyloxy, hydroxyl, alkoxycarbonyl, acyloxy, 1-alkoxyiminoalkyl, alkylcarbonyl or acylamino group) or a nitrogen-containing heterocyclic group; R' is an amino group which may optionally be acylated or protected; and X is a hydrogen atom or a methoxy group, or a salt or ester thereof, and methods of producing said compound (Ia) which may be shown as follows wherein the symbols have the same meanings as respectively defined above, and intermediates for preparing the compound (Ia) and methods of producing them. The compound (Ia) has improved antimicrobial and β-lactamase- inhibitory activities and is of value as drugs for human beings and domesticated animals.

  式中的 1-磺基-2-氧氮杂环丁烷衍生物 其中 R8 为-COQ°（Q°为氨基，可任选被保护或取代）、-COQ5（Q5 为羟基，可任选被保护）、-(CH2)na- R4a（na 为 1 至 3 的整数：R4a 是氢原子或氨基甲酰氨基、N-硫代氨基甲酰氨基、氨基甲酰基、氨基甲酰氧基、N-硫代氨基甲酰氧基、卤代烷基羰基氨基甲酰氧基、烷基磺酰氧基、吡啶基、烷氧基、烷基亚磺酰基、烷基磺酰基、卤代烷基羰基氧基、羟基、烷氧基羰基、酰氧基、1-烷氧基亚氨基烷基、烷基羰基或酰氨基）或含氮杂环基团；R'是可选择酰化或保护的氨基；X是氢原子或甲氧基，或其盐或酯，以及生产所述化合物（Ia）的方法，可如下所示 其中符号的含义分别与上述定义相同，以及制备化合物（Ia）的中间体及其生产方法。化合物（Ia）具有更好的抗菌和抑制β-内酰胺酶的活性，具有作为人类和驯养动物药物的价值。
• US4572801A
  申请人：——

  公开号：US4572801A

  公开（公告）日：1986-02-25
• US4673739A
  申请人：——

  公开号：US4673739A

  公开（公告）日：1987-06-16
• 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04572801A1

  公开（公告）日：1986-02-25

  Disclosed are compounds of the general formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a lower alkyl group and R.sup.2 is a hydrogen atom or an ester residue, said derivative having the (3S,4S)-configuration; and pharmaceutically acceptable salts and esters thereof. The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.

  揭示的是一般式为：##STR1##的化合物，其中R.sup.1是氢原子或较低的烷基基团，R.sup.2是氢原子或酯基团，所述衍生物具有(3S,4S)-构型；以及其药学上可接受的盐和酯。这些化合物具有抗微生物和/或β-内酰胺酶抑制活性，并且作为人类和驯养动物的药物具有价值。